Stockscreener 앱 받기
8.1425
1.81%
-0.1575
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
BioCryst’s Chief R&D Officer Resigns Amid CEO Decision - TipRanks
BioCryst’s chief R&D officer to depart for CEO role elsewhere By Investing.com - Investing.com Australia
BioCryst Announces Departure of Dr. Helen Thackray - GlobeNewswire
BioCryst's R&D Chief Departs Following CEO Race: What This Means for ORLADEYO and 2 Pipeline Drugs - Stock Titan
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome - TipRanks
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs - Stock Titan
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
Transcript : BioCryst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level - Stocktwits
BioCryst Pharmaceuticals Soars 15.35% on Strong Earnings - AInvest
Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge - Investing.com
BioCryst Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
BioCryst Pharmaceuticals Reports Impressive Q2 EarningsNews and Statistics - IndexBox
BioCryst Keeps Momentum With Strong ORLADEYO Sales And Rising Profits - Finimize
BioCryst Pharma soars 6.4% as Q2 results crush expectations - Investing.com
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates - Investing.com
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
BioCryst Pharmaceuticals' Q2 Adjusted Earnings Swings to Profit, Revenue Rises; Maintains 2025 Guidance - MarketScreener
BioCryst Pharmaceuticals: A High-Conviction Biotech Play with a Defensible Moat in Rare Disease Innovation - AInvest
BioCryst Reports Strong Q2 2025 Financial Performance - TipRanks
Is This the Dip to Buy in BioCryst Pharmaceuticals Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
BioCryst (BCRX) Q2 Revenue Jumps 50% - The Motley Fool
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $163.4M, vs. FactSet Est of $149.8M - MarketScreener
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.15 per Share, vs. FactSet Est of $0.01 - MarketScreener
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Is it the right time to buy BioCryst Pharmaceuticals Inc. stockTrack high-yield stocks before they peak - Jammu Links News
What is the dividend policy of BioCryst Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastTrack top-performing stocks effortlessly - Jammu Links News
How strong is BioCryst Pharmaceuticals Inc. company’s balance sheetCapitalize on emerging industry trends - Jammu Links News
What makes BioCryst Pharmaceuticals Inc. stock price move sharplyMaximize gains with expert analysis - Jammu Links News
How does BioCryst Pharmaceuticals Inc. compare to its industry peersDiscover breakthrough stocks before the crowd - Jammu Links News
Is BioCryst Pharmaceuticals Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
When is BioCryst Pharmaceuticals Inc. stock expected to show significant growthStrong return on investment - Jammu Links News
How volatile is BioCryst Pharmaceuticals Inc. stock compared to the marketBuild wealth steadily with smart stock selection - Jammu Links News
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
What are the technical indicators suggesting about BioCryst Pharmaceuticals Inc.Double or triple returns - Jammu Links News
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
Is BioCryst Pharmaceuticals Inc. a good long term investmentFree Stock Market Query - Jammu Links News
Is BioCryst Pharmaceuticals Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News
BioCryst Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected to Rise 37% YoY - AInvest
BioCryst Announces New President Amid Leadership Change - The Globe and Mail
0.47%
2.98%
자본화:
|
볼륨(24시간):